EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Glioblastoma Therapy: Past, Present and Future

Elena Obrador iD, Paz Moreno-Murciano iD, María Oriol-Caballo iD, Rafael López-Blanch, Begoña Pineda, Julia Lara Gutiérrez-Arroyo, Alba Loras iD, Luis G Gonzalez-Bonet iD, Conrado Martinez-Cadenas iD, José M Estrela iD, María Ángeles Marqués-Torrejón iD

International Journal of Molecular Sciences · 21.02.2024 · 25 (5) · 2529

DOI: 10.3390/ijms25052529 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 21.02.2024. Verfasst von Elena Obrador und 10 weiteren Autor:innen. Beteiligte Einrichtung: Scientia BioTech S.L., 46002 Valencia, Spain. Hauptthemen laut MEDLINE: Glioblastoma, Glioma, Hyperthermia, Induced. Die Arbeit wurde bisher 271-mal zitiert (Crossref) und nennt 1109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scientia BioTech S.L., MCIN/AEI/10.13039/501100011033/, Scientia BioTech S.L.-Spain.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GB) stands out as the most prevalent and lethal form of brain cancer. Although great efforts have been made by clinicians and researchers, no significant improvement in survival has been achieved since the Stupp protocol became the standard of care (SOC) in 2005. Despite multimodality treatments, recurrence is almost universal with survival rates under 2 years after diagnosis. Here, we discuss the recent progress in our understanding of GB pathophysiology, in particular, the importance of glioma stem cells (GSCs), the tumor microenvironment conditions, and epigenetic mechanisms involved in GB growth, aggressiveness and recurrence. The discussion on therapeutic strategies first covers the SOC treatment and targeted therapies that have been shown to interfere with different signaling pathways (pRB/CDK4/RB1/P16ink4, TP53/MDM2/P14arf, PI3k/Akt-PTEN, RAS/RAF/MEK, PARP) involved in GB tumorigenesis, pathophysiology, and treatment resistance acquisition. Below, we analyze several immunotherapeutic approaches (i.e., checkpoint inhibitors, vaccines, CAR-modified NK or T cells, oncolytic virotherapy) that have been used in an attempt to enhance the immune response against GB, and thereby avoid recidivism or increase survival of GB patients. Finally, we present treatment attempts made using nanotherapies (nanometric structures having active anti-GB agents such as antibodies, chemotherapeutic/anti-angiogenic drugs or sensitizers, radionuclides, and molecules that target GB cellular receptors or open the blood–brain barrier) and non-ionizing energies (laser interstitial thermal therapy, high/low intensity focused ultrasounds, photodynamic/sonodynamic therapies and electroporation). The aim of this review is to discuss the advances and limitations of the current therapies and to present novel approaches that are under development or following clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaGliomaHyperthermia, InducedHumansPhosphatidylinositol 3-KinasesCombined Modality TherapyTumor Microenvironment

Stichwörter der Autor:innen

glioblastomaimmunotherapynanotherapynon-ionizing radiationtargeted therapy

Substanzen

Phosphatidylinositol 3-Kinases

Autor:innen und Institutionen

  • Scientia BioTech S.L., 46002 Valencia, Spain.
  • Department of Physiology, Faculty of Medicine and Odontology, University of Valencia, 46010 Valencia, Spain.
  • Department of Medicine, Jaume I University of Castellon, 12071 Castellon, Spain.
  • Department of Neurosurgery, Castellon General University Hospital, 12004 Castellon, Spain.
  • Department of Physiology, Faculty of Pharmacy, University of Valencia, 46100 Burjassot, Spain.

ORCID-Profile: Elena Obrador, Paz Moreno-Murciano, María Oriol-Caballo, Alba Loras, Luis G Gonzalez-Bonet, Conrado Martinez-Cadenas, José M Estrela, María Ángeles Marqués-Torrejón

Förderung

  • Scientia BioTech S.L.
  • MCIN/AEI/10.13039/501100011033/
  • Scientia BioTech S.L.-Spain
  • European Union-Next generation EU
  • ‘Maria Zambrano’ research contract
  • Ramon y Cajal Research Fellow

Zitieren

APA

Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J. L., Loras, A., Gonzalez-Bonet, L. G., Martinez-Cadenas, C., Estrela, J. M., & Marqués-Torrejón, M. Á. (2024). Glioblastoma Therapy: Past, Present and Future. International Journal of Molecular Sciences, 25(5), 2529. https://doi.org/10.3390/ijms25052529

Vancouver

Obrador E, Moreno-Murciano P, Oriol-Caballo M, López-Blanch R, Pineda B, Gutiérrez-Arroyo JL, et al. Glioblastoma Therapy: Past, Present and Future. International Journal of Molecular Sciences. 2024;25(5):2529. doi:10.3390/ijms25052529

BibTeX
@article{Obrador2024,
  author = {Obrador, Elena and Moreno-Murciano, Paz and Oriol-Caballo, María and López-Blanch, Rafael and Pineda, Begoña and Gutiérrez-Arroyo, Julia Lara and Loras, Alba and Gonzalez-Bonet, Luis G and Martinez-Cadenas, Conrado and Estrela, José M and Marqués-Torrejón, María Ángeles},
  title = {Glioblastoma Therapy: Past, Present and Future},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {5},
  pages = {2529},
  doi = {10.3390/ijms25052529}
}
Kostenlos starten →